Why Propanc Biopharma, Inc.’s (PPCB) Stock Is Down 10.30%
As of Friday, August 22, Propanc Biopharma, Inc.’s PPCB share price has dipped by 10.30%, which has investors questioning if this is right time to buy.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Omar Beirat
Jack Gilleland
| Share Statistics | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.8 | $213.9 | 2% |
|
| Shares Out (Mil) | 0.7 | 55.4 | 4% |
|
| Institutional Ownership | 2.8% | 93.3% | 3% |
|
| Float (Mil) | 0.3 | 40.6 | 1% |
|
| Beta | na | 0.98 | na |
|
| Avg Daily Volume (000s) | 12 | 597 | 18% |
|
| Price Change (52-week) |
(99.1%) | 40.9% | 2% |
|
| Growth | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (56.7%) | (10.7%) | 6% |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($44) | 22% |
|
| EPS (TTM) | ($85.377) | ($1.400) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($34) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1 | $135 | 5% |
|
| Valuation | PPCB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.24 | 1.97 | 5% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | PPCB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (159.8%) | (47.5%) | 2% |
|
| ROE | (211.0%) | (51.9%) | 4% |
|
| Liabilities to Assets | 31.5% | 29.7% | 22% |
|
| F-Score | 3 | 3 | na |
|
Propanc Biopharma, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors